Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
POSTER: MM-1484 DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features
María‐Victoria Mateos, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Meletios A Dimopoulos, Claudio Cerchione, Nick Pirooz, Astrid McKeown, Chee Paul Lin, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opa, Vânia Hungria (2025). POSTER: MM-1484 DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01370-9.
Article48 days agoEfficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.
Marcelo Pitombeira de Lacerda, Meletios A Dimopoulos, Luděk Pour, Kihyun Kim, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Anna Sureda, Ivan Spicka, Paweł Robak, Marek Hus, Vera Zherebtsova, Merit Hanna, Vinay Jadhav, Nicholas Pirooz, Ianire Garrobo-Calleja, Lydia Eccersley, Vânia Hungria, Meral Beksaç (2025). Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7548.
Article48 days agoIsatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
Sikander Ailawadhi, Ivan Špıčka, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Meletios A Dimopoulos, Péter Rajnics, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier P. Leleu, Tondre T. Buck, Jiří Minařík, Rick Zhang, Dorothée Sémiond, Maya Stefanova-Urena, Philippe Moreau (2025). Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7506.
Article48 days agoMM-1484: DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features
María‐Victoria Mateos, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Meletios A Dimopoulos, Claudio Cerchione, Nick Pirooz, Astrid McKeown, Chee Paul Lin, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opa, Vânia Hungria (2025). MM-1484: DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02741-7.
Article48 days agoIsatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome
Jin Lu, Albert Oriol, Alejandro Berkovits, Andrew Spencer, César Cinesi Gómez, Chunrui Li, Claudio Cerchione, Fei Li, Fredrik Schjesvold, Gurdeep Parmar, Ivan Špıčka, Marek Hus, Maria Del Rosario Custidiano, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Sikander Ailawadhi, Silvia Ling, Vânia Hungria, Xavier Leleu, Florence Suzan Teisserenc, Maya Stefanova-Urena, Rick Zhang, Victorine Koch, Dorothée Sémiond (2025). Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-5812.
Article48 days ago